Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Discover how compounded semaglutide enhances the body's natural insulin function, aiding in blood sugar control and diabetes ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Wegovy is a GLP-1 agonist containing semaglutide ... though it’s not a weight loss medication. Starting dose: 0.25 mg weekly for 4 weeks. Gradually increased to a maximum dose of 2.0 mg weekly.